Skip to main content

Table 2 ORs and 95 % CIs for NHL by markers of HCV and HBV. Italy, 1999–2014

From: Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy

 

NHL

Controls

 
 

N (%)

N (%)

OR (95 % CI)a

HCV

571

1004

 

 Anti-HCV-

492 (86.2)

940 (93.6)

1b

 Anti-HCV+

79 (13.8)

64 (6.4)

2.39 (1.66–3.43)

   HCV RNA -c

14 (2.5)

27 (2.7)

0.98 (0.50–1.92)

   HCV RNA +

63 (11.1)

35 (3.5)

3.51 (2.25–5.47)

HBVd

570

997

 

 HBsAg-/anti-HBs-/anti-HBc-

359 (63.0)

609 (61.1)

1b

 HBsAg-/anti-HBs+/anti-HBc+

90 (15.8)

179 (18.0)

0.78 (0.58–1.06)

 HBsAg-/anti-HBs+/anti-HBc-

53 (9.3)

122 (12.2)

0.87 (0.59–1.29)

 HBsAg-/anti-HBs-/anti-HBc+

47 (8.2)

70 (7.0)

1.10 (0.73–1.65)

 HBsAg+

21 (3.7)

17 (1.7)

1.95 (1.00–3.81)

  1. NHL non-Hodgkin lymphoma, OR odds ratio, CI confidence interval
  2. aEstimated using unconditional logistic regression models adjusted for gender, age, study center, years of education, and place of birth; bReference category; cInformation on HCV RNA was missing for 2 cases and 2 controls; d1 case and 7 controls without complete information on all HBV markers were excluded
Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us